DE19813802A1 - Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen - Google Patents

Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen

Info

Publication number: DE19813802A1
Authority: DE; Germany
Prior art keywords: propolis; inhibition; use according; hiv; viruses
Prior art date: 1998-03-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

DE1998113802

Other languages

German (de)

English (en)

Inventor

Alois G Hiszem

Ortwin Faff

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Retro-Tech GmbH Gesellschaft fur Retrovirale Technologie

Original Assignee

Retro-Tech GmbH Gesellschaft fur Retrovirale Technologie

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-03-27

Filing date

1998-03-27

Publication date

1999-11-11

1998-03-27 Application filed by Retro-Tech GmbH Gesellschaft fur Retrovirale Technologie filed Critical Retro-Tech GmbH Gesellschaft fur Retrovirale Technologie

1998-03-27 Priority to DE1998113802 priority Critical patent/DE19813802A1/de

1999-03-25 Priority to PCT/DE1999/000902 priority patent/WO1999049830A2/fr

1999-11-11 Publication of DE19813802A1 publication Critical patent/DE19813802A1/de

Status Ceased legal-status Critical Current

Links

241000241413 Propolis Species 0.000 title claims abstract description 38
229940069949 propolis Drugs 0.000 title claims abstract description 38
230000005764 inhibitory process Effects 0.000 title claims abstract description 25
230000003612 virological effect Effects 0.000 title claims description 8
102000039446 nucleic acids Human genes 0.000 title claims description 7
108020004707 nucleic acids Proteins 0.000 title claims description 7
150000007523 nucleic acids Chemical class 0.000 title claims description 7
230000000840 anti-viral effect Effects 0.000 title abstract description 9
230000000694 effects Effects 0.000 claims abstract description 24
241000700605 Viruses Species 0.000 claims abstract description 17
239000000284 extract Substances 0.000 claims abstract description 17
102100034343 Integrase Human genes 0.000 claims abstract description 13
230000010076 replication Effects 0.000 claims abstract description 12
108010092799 RNA-directed DNA polymerase Proteins 0.000 claims abstract description 11
201000010099 disease Diseases 0.000 claims abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
239000000126 substance Substances 0.000 claims abstract description 6
238000002560 therapeutic procedure Methods 0.000 claims abstract description 6
230000002255 enzymatic effect Effects 0.000 claims abstract description 5
238000004113 cell culture Methods 0.000 claims abstract description 4
230000002401 inhibitory effect Effects 0.000 claims abstract 4
239000002537 cosmetic Substances 0.000 claims abstract 2
235000013305 food Nutrition 0.000 claims abstract 2
239000003814 drug Substances 0.000 claims description 14
239000004480 active ingredient Substances 0.000 claims description 9
229940079593 drug Drugs 0.000 claims description 6
230000001747 exhibiting effect Effects 0.000 claims 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 claims 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 claims 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 claims 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 claims 1
238000000338 in vitro Methods 0.000 claims 1
238000001727 in vivo Methods 0.000 claims 1
241000725303 Human immunodeficiency virus Species 0.000 abstract description 17
208000030507 AIDS Diseases 0.000 abstract description 10
239000003112 inhibitor Substances 0.000 abstract description 9
230000001413 cellular effect Effects 0.000 abstract description 7
238000010790 dilution Methods 0.000 abstract description 7
239000012895 dilution Substances 0.000 abstract description 7
108010078851 HIV Reverse Transcriptase Proteins 0.000 abstract description 5
239000000287 crude extract Substances 0.000 abstract description 5
230000009471 action Effects 0.000 abstract description 4
206010028980 Neoplasm Diseases 0.000 abstract description 3
GLWHPRRGGYLLRV-XLPZGREQSA-N [[(2s,3s,5r)-3-azido-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](N=[N+]=[N-])C1 GLWHPRRGGYLLRV-XLPZGREQSA-N 0.000 abstract description 3
201000011510 cancer Diseases 0.000 abstract description 3
208000006454 hepatitis Diseases 0.000 abstract description 3
231100000283 hepatitis Toxicity 0.000 abstract description 3
208000032839 leukemia Diseases 0.000 abstract description 2
210000005105 peripheral blood lymphocyte Anatomy 0.000 abstract description 2
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 abstract description 2
230000002779 inactivation Effects 0.000 abstract 1
231100000028 nontoxic concentration Toxicity 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 13
238000011161 development Methods 0.000 description 10
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
239000013543 active substance Substances 0.000 description 5
230000001177 retroviral effect Effects 0.000 description 5
229940124597 therapeutic agent Drugs 0.000 description 5
238000012360 testing method Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
241000894006 Bacteria Species 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
241000713772 Human immunodeficiency virus 1 Species 0.000 description 3
206010034133 Pathogen resistance Diseases 0.000 description 3
230000000798 anti-retroviral effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
210000004698 lymphocyte Anatomy 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
239000000758 substrate Substances 0.000 description 3
241000196324 Embryophyta Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
108010061833 Integrases Proteins 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
239000004365 Protease Substances 0.000 description 2
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
239000000427 antigen Substances 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000002427 irreversible effect Effects 0.000 description 2
239000000203 mixture Substances 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
239000002777 nucleoside Substances 0.000 description 2
150000003833 nucleoside derivatives Chemical class 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000002904 solvent Substances 0.000 description 2
241000894007 species Species 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 1
241000208195 Buxaceae Species 0.000 description 1
102000019034 Chemokines Human genes 0.000 description 1
108010012236 Chemokines Proteins 0.000 description 1
241000218631 Coniferophyta Species 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
241000233866 Fungi Species 0.000 description 1
208000031886 HIV Infections Diseases 0.000 description 1
108010010369 HIV Protease Proteins 0.000 description 1
208000037357 HIV infectious disease Diseases 0.000 description 1
241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
241000257303 Hymenoptera Species 0.000 description 1
235000017309 Hypericum perforatum Nutrition 0.000 description 1
244000141009 Hypericum perforatum Species 0.000 description 1
206010061217 Infestation Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
238000012356 Product development Methods 0.000 description 1
-1 RNAse Proteins 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
229940125528 allosteric inhibitor Drugs 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000036436 anti-hiv Effects 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000003124 biologic agent Substances 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000007385 chemical modification Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
230000007123 defense Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000009510 drug design Methods 0.000 description 1
230000007247 enzymatic mechanism Effects 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000004744 fabric Substances 0.000 description 1
238000001415 gene therapy Methods 0.000 description 1
230000036541 health Effects 0.000 description 1
239000000321 herbal drug Substances 0.000 description 1
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
PHOKTTKFQUYZPI-UHFFFAOYSA-N hypericin Natural products Cc1cc(O)c2c3C(=O)C(=Cc4c(O)c5c(O)cc(O)c6c7C(=O)C(=Cc8c(C)c1c2c(c78)c(c34)c56)O)O PHOKTTKFQUYZPI-UHFFFAOYSA-N 0.000 description 1
BTXNYTINYBABQR-UHFFFAOYSA-N hypericin Chemical compound C12=C(O)C=C(O)C(C(C=3C(O)=CC(C)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 BTXNYTINYBABQR-UHFFFAOYSA-N 0.000 description 1
229940005608 hypericin Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000037125 natural defense Effects 0.000 description 1
239000005445 natural material Substances 0.000 description 1
239000002547 new drug Substances 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
125000003729 nucleotide group Chemical group 0.000 description 1
244000045947 parasite Species 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
SSKVDVBQSWQEGJ-UHFFFAOYSA-N pseudohypericin Natural products C12=C(O)C=C(O)C(C(C=3C(O)=CC(O)=C4C=33)=O)=C2C3=C2C3=C4C(C)=CC(O)=C3C(=O)C3=C(O)C=C(O)C1=C32 SSKVDVBQSWQEGJ-UHFFFAOYSA-N 0.000 description 1
238000000746 purification Methods 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
238000011160 research Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
231100000041 toxicology testing Toxicity 0.000 description 1
235000011178 triphosphate Nutrition 0.000 description 1
239000001226 triphosphate Substances 0.000 description 1
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
238000013024 troubleshooting Methods 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
229960002555 zidovudine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE1998113802 1998-03-27 1998-03-27 Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen Ceased DE19813802A1 (de)

Priority Applications (2)

Application Number	Priority Date	Filing Date	Title
DE1998113802 DE19813802A1 (de)	1998-03-27	1998-03-27	Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
PCT/DE1999/000902 WO1999049830A2 (fr)	1998-03-27	1999-03-25	Action antivirale de la propolis par inhibition des polymerases d'acides nucleiques viraux

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE1998113802 DE19813802A1 (de)	1998-03-27	1998-03-27	Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen

Publications (1)

Publication Number	Publication Date
DE19813802A1 true DE19813802A1 (de)	1999-11-11

Family

ID=7862702

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE1998113802 Ceased DE19813802A1 (de)	1998-03-27	1998-03-27	Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen

Country Status (2)

Country	Link
DE (1)	DE19813802A1 (fr)
WO (1)	WO1999049830A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7888466B2 (en)	1996-01-11	2011-02-15	Human Genome Sciences, Inc.	Human G-protein chemokine receptor HSATU68
EP2275557A1 (fr)	2000-04-12	2011-01-19	Human Genome Sciences, Inc.	Protéines de fusion d'albumine
CA2413160A1 (fr)	2000-06-15	2001-12-20	Human Genome Sciences, Inc.	Facteur de necrose tumorale humain delta et epsilon
EP2990417A1 (fr)	2001-12-21	2016-03-02	Human Genome Sciences, Inc.	Protéines de fusion d'albumine et insuline
US7892563B2 (en)	2003-05-20	2011-02-22	Wyeth Holdings Corporation	Methods for treatment of severe acute respiratory syndrome (SARS)
DE102005031361A1 (de) *	2005-06-30	2007-01-04	Biotronik Vi Patent Ag	Verwendung von Propolis als Beschichtungsmaterial für medizinische Implantate
AU2006344395B2 (en)	2005-10-13	2013-05-02	Human Genome Sciences, Inc.	Methods and compositions for use in treatment of patients with autoantibody positive diseases
JP2010535156A (ja)	2007-08-03	2010-11-18	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	ウイルスポリメラーゼ阻害剤
MX2010006313A (es)	2007-12-19	2010-06-25	Boehringer Ingelheim Int	Inhibidores de la polimerasa virica.
WO2011056650A2 (fr)	2009-10-27	2011-05-12	Michael Zasloff	Méthodes et compositions utilisées dans le cadre du traitement et de la prévention d'infections virales
WO2011066260A2 (fr)	2009-11-25	2011-06-03	Michael Zasloff	Formulations comprenant des aminostérols

Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1956353A1 (de) *	1969-11-08	1971-05-19	Schering Ag	Neue Aluminium-dien-polymere
DE2045681A1 (en) *	1970-09-16	1972-03-23	Schering Ag	Aluminium-diene polymers, for prepn of - catalysts for (co) polymerisation
DE19516200A1 (de) *	1995-05-08	1996-11-14	Merck Patent Gmbh	Dendrimere mit flüssigkristallinen Eigenschaften, Verfahren zu ihrer Herstellung, Verwendung
WO1997032918A2 (fr) *	1996-03-05	1997-09-12	Massachusetts Institute Of Technology	Dendrimeres d'organosilicium contenant un metal du grouge 4
WO1997032908A1 (fr) *	1996-03-05	1997-09-12	Massachusetts Institute Of Technology	Dendrimeres d'organosilicium contenant des metaux du groupe 4

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2659234B1 (fr) *	1990-03-12	1994-07-01	Fileco Sa	Composition therapeutique contenant un compose phenol et de la propolis utile contre les virus a capside lipidique, notamment les virus de l'herpes.
US5449794A (en) *	1991-02-15	1995-09-12	Jasmine Fockerman	Benzopyran phenol derivatives for use as antibacterial agents

1998
- 1998-03-27 DE DE1998113802 patent/DE19813802A1/de not_active Ceased
1999
- 1999-03-25 WO PCT/DE1999/000902 patent/WO1999049830A2/fr not_active Ceased

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE1956353A1 (de) *	1969-11-08	1971-05-19	Schering Ag	Neue Aluminium-dien-polymere
DE2045681A1 (en) *	1970-09-16	1972-03-23	Schering Ag	Aluminium-diene polymers, for prepn of - catalysts for (co) polymerisation
DE19516200A1 (de) *	1995-05-08	1996-11-14	Merck Patent Gmbh	Dendrimere mit flüssigkristallinen Eigenschaften, Verfahren zu ihrer Herstellung, Verwendung
WO1997032918A2 (fr) *	1996-03-05	1997-09-12	Massachusetts Institute Of Technology	Dendrimeres d'organosilicium contenant un metal du grouge 4
WO1997032908A1 (fr) *	1996-03-05	1997-09-12	Massachusetts Institute Of Technology	Dendrimeres d'organosilicium contenant des metaux du groupe 4

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CA 116:703v *
CA 119:131029g *
CA 124:194307c *
CA 127:126635v CA 124:249859s *
CA 95:166958e *
Drugs in der Experimental and Chemical Research (1997) 23(2), S. 89-96 *
HOUBEN-WEYL: Methoden der org. Chemie, 1982, Bd. 13/3a, S. 476-479 *
HU 64 862, ref. in Derwent Abstr. 94-138102/17 *
J.Am.Chem.Soc. 113, S. 3623-3625 *
WO 97/24115 ref in *

Also Published As

Publication number	Publication date
WO1999049830A2 (fr)	1999-10-07
WO1999049830A3 (fr)	2000-03-09

Publication	Publication Date	Title
DE69306969T2 (de)	1997-05-07	Therapeutisches anti-hiv oligonukleotid und arzneimittel
DE69635671T2 (de)	2006-09-07	Verwendung von roxithromycin zur herstellung eines medikaments zur verbesserung der biologischen und antiviralen aktivität von protease-inhibitoren
KR20010005603A (ko)	2001-01-15	인간면역결핍성 바이러스 및 그밖의 감염성 질환의 항미생물적 예방 및 치료
DE19813802A1 (de)	1999-11-11	Anti-virale Wirkung von Propolis durch Inhibition viraler Nukleinsäure Polymerasen
DE69631158T2 (de)	2004-08-26	Verbindungen und deren verwendung zur behandlung von infektiösen erkrankungen
HU201672B (en)	1990-12-28	Process for producing pharmaceutical compositions comprising podophyllotoxin
DE202009017847U1 (de)	2010-06-17	Zusammensetzung zur Prävention und Behandlung von Virusinfektionen
EP1599194A1 (fr)	2005-11-30	Utilisation de substances actives destinees a la prophylaxie et/ou la therapie de maladies virales
US6117903A (en)	2000-09-12	Extracts of Salvia species having antiviral activity
DE60032915T2 (de)	2007-10-25	Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen
DE69328667T2 (de)	2001-02-08	Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
DE60118592T2 (de)	2007-05-16	Verbindungen aus phyllanthus zur prävention und/oder behandlung von erkrankungen im zusammenhang mit einem retrovirus
DE69535366T2 (de)	2007-10-11	Zusammensetzung zur behandlung und vorbeugung von hiv-1 infektionen, welche mindestens zwei verschiedene hiv-1 reverse transcriptase inhibitoren enthalt
RU2182828C1 (ru)	2002-05-27	Композиция, обладающая антивич и антигерпесной активностью
DE3885798T2 (de)	1994-05-19	Proteinhaltiges Polysaccharid zur Behandlung retroviraler Infektionen.
EP1395270B1 (fr)	2014-07-23	Utilisation d'éléments de phyllanthus pour la préparation d'un médicament pour la prévention ou le traitement d'une infection par le virus de l'hepatite b résistant
EP0121363A2 (fr)	1984-10-10	Compositions pharmaceutiques contenant un pyréthroide
DE4320597A1 (de)	1995-01-05	Verwendung von Polyphosphaten zur antiviralen Therapie und als Immunmodulatoren
DE69619827T2 (de)	2002-11-07	Verwendung von alicyclischen diaminen als immunomodulatoren
DE3825397C2 (de)	1997-08-21	Verwendung von Papaverin und seinen Salzen zur Bekämpfung von AIDS
EP4196099B1 (fr)	2025-02-12	Dérivés diphényliques pour l'utilisation dans la thérapie de maladies virales, en particulier d'infections corona, en particulier de covid-19
DE3744345A1 (de)	1989-07-06	Pharmazeutische zubereitung zur stimulierung der makrophagenaktivitaet
DE69722025T2 (de)	2004-04-01	Verfahren zur unterbrechung der desoxyribonukleotidtriphosphat-biosynthese
EP1644040B1 (fr)	2009-12-09	Utilisation de combinaisons d'inhibiteurs de la transcriptase inverse et d'inhibiteurs de l'adn-polymerase codee par virus
DE60104288T2 (de)	2005-08-25	Antivirale therapie

Legal Events

Date	Code	Title
1999-11-11	OP8	Request for examination as to paragraph 44 patent law
1999-12-16	8122	Nonbinding interest in granting licenses declared
2001-05-31	8131	Rejection